Imeglimin
This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Name
- Imeglimin
- Accession Number
- DB12509
- Description
Imeglimin has been used in trials studying the treatment of Type 2 Diabetes Mellitus.
- Type
- Small Molecule
- Groups
- Investigational
- Structure
Structure for Imeglimin (DB12509)
- Weight
- Average: 155.205
Monoisotopic: 155.117095439 - Chemical Formula
- C6H13N5
- Synonyms
- Imeglimin
- Imeglimina
- Iméglimine
- Imegliminum
- External IDs
- EMD-387008
- EMD387008
Pharmacology
Accelerate your drug discovery research with the industry’s only fully connected ADMET dataset, ideal for:Accelerate your drug discovery research with our fully connected ADMET dataset- Indication
- Not Available
- Contraindications & Blackbox Warnings
Contraindications & Blackbox WarningsWith our commercial data, access important information on dangerous risks, contraindications, and adverse effects.Our Blackbox Warnings cover Risks, Contraindications, and Adverse Effects- Pharmacodynamics
- Not Available
- Mechanism of action
- Not Available
- Absorption
- Not Available
- Volume of distribution
- Not Available
- Protein binding
- Not Available
- Metabolism
- Not Available
- Route of elimination
- Not Available
- Half-life
- Not Available
- Clearance
- Not Available
- Adverse Effects
Reduce medical errorsand improve treatment outcomes with our comprehensive & structured data on drug adverse effects.Reduce medical errors & improve treatment outcomes with our adverse effects data- Toxicity
- Not Available
- Affected organisms
- Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Categories
- Drug Categories
- Not Available
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as aminotriazines. These are organic compounds containing an amino group attached to a triazine ring.
- Kingdom
- Organic compounds
- Super Class
- Organoheterocyclic compounds
- Class
- Triazines
- Sub Class
- Aminotriazines
- Direct Parent
- Aminotriazines
- Alternative Parents
- 1,3,5-triazines / Guanidines / Propargyl-type 1,3-dipolar organic compounds / Carboximidamides / Azacyclic compounds / Hydrocarbon derivatives / Amines
- Substituents
- 1,3,5-triazine / Aliphatic heteromonocyclic compound / Amine / Aminotriazine / Azacycle / Carboximidamide / Guanidine / Hydrocarbon derivative / Organic 1,3-dipolar compound / Organic nitrogen compound
- Molecular Framework
- Aliphatic heteromonocyclic compounds
- External Descriptors
- Not Available
Chemical Identifiers
- UNII
- UU226QGU97
- CAS number
- 775351-65-0
- InChI Key
- GFICWFZTBXUVIG-SCSAIBSYSA-N
- InChI
- InChI=1S/C6H13N5/c1-4-8-5(7)10-6(9-4)11(2)3/h4H,1-3H3,(H3,7,8,9,10)/t4-/m1/s1
- IUPAC Name
- (6R)-N4,N4,6-trimethyl-1,6-dihydro-1,3,5-triazine-2,4-diamine
- SMILES
- C[C@@H]1NC(N)=NC(=N1)N(C)C
References
- General References
- Not Available
- External Links
- PubChem Compound
- 24812808
- PubChem Substance
- 347828740
- ChemSpider
- 26232690
- ZINC
- ZINC000034380900
- Wikipedia
- Imeglimin
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 2 Completed Treatment Type 2 Diabetes Mellitus 1 1 Completed Other Healthy Volunteers 1 1 Completed Treatment Bioequivalence 1 1 Completed Treatment Hepatic Impairment 1 1 Completed Treatment Qt Interval, Variation in 1 1 Completed Treatment Type 2 Diabetes Mellitus 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 4.63 mg/mL ALOGPS logP -0.92 ALOGPS logP -0.69 ChemAxon logS -1.5 ALOGPS pKa (Strongest Acidic) 17.1 ChemAxon pKa (Strongest Basic) 10.21 ChemAxon Physiological Charge 2 ChemAxon Hydrogen Acceptor Count 5 ChemAxon Hydrogen Donor Count 2 ChemAxon Polar Surface Area 66.01 Å2 ChemAxon Rotatable Bond Count 0 ChemAxon Refractivity 43.29 m3·mol-1 ChemAxon Polarizability 16.62 Å3 ChemAxon Number of Rings 1 ChemAxon Bioavailability 1 ChemAxon Rule of Five Yes ChemAxon Ghose Filter No ChemAxon Veber's Rule No ChemAxon MDDR-like Rule No ChemAxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted GC-MS Spectrum - GC-MS Predicted GC-MS Not Available Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS Not Available
Drug created on October 20, 2016 22:40 / Updated on February 21, 2021 18:53